Global Urticaria Drugs Market 2018-2022 to Post 10% CAGR | Technavio
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190104005250/en/
Technavio has published a new market research report on the global urticaria drugs market from 2018-2022. (Graphic: Business Wire)
The introduction of biologics for the treatment of urticaria is one of the major trends being witnessed in the . There is an unmet need for disease-modifying biologics for the treatment of urticaria. Extensive research has been conducted to evaluate factors such as safety and efficacy, mechanism of action, and dosing of biologics like XOLAIR (omalizumab), rituximab, and intravenous immunoglobulin for urticaria. Out of these, the anti-19E monoclonal antibody omalizumab is the first and only FDA-approved biologic for the management of chronic urticaria.
According to Technavio analysts, one of the key factors contributing to the growth of the global urticaria drugs market is the guidelines for management of urticaria patients:
Global urticaria drugs market: Guidelines for management of urticaria patients
Standards of Care Committee of the British Society for Allergy and Clinical Immunology (BSACI) have prepared the standard guidelines for the management of patients with chronic urticaria and angioedema. These guidelines are based on evidence followed with the expert opinion and are aimed at both adult physicians and pediatricians practicing on allergy-related diseases Using a Web-based system, all BSACI members were included for designing of these guidelines in the consultation process. The Standards of Care Committee carefully considered comments and suggestions of all the members.
According to a senior analyst at Technavio for research on infectious and rare diseases, “A consensus was reached by the experts on the committee on areas where there is a lack of evidence. The management guidelines include clinical classification, etiology, investigations, diagnosis, treatment guidance along with special sections on children suffering from urticaria and the use of antihistamines in pregnant women or breastfeeding women. Organizations are taking various initiatives for implementing the guideline for improving urticaria disease management.”
Global urticaria drugs market: Segmentation analysis
The global urticaria drugs market research report provides market segmentation by application (acute urticaria and chronic urticaria), by end-user (hospitals and clinics, ASCs, dialysis centers, and others), and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
The acute urticaria segment held the largest market share in 2017, accounting for nearly 80% of the market. This application segment is expected to dominate the global market throughout the forecast period.
EMEA led the market in 2017 with a market share of 40%. This region is expected to dominate the market through 2022, however there will be a decrease in its market share.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market LandscapeMarket ecosystem Market characteristics Market segmentation analysis
Market SizingMarket definition Market size and forecast
Five Forces Analysis
Geographical SegmentationRegional comparison Key leading countries
Vendor LandscapeVendors covered Vendor classification Market positioning of vendors Competitive scenario
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20190104005250/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2019.
PUB: 01/04/2019 11:25 AM/DISC: 01/04/2019 11:25 AM